Literature DB >> 11521748

Involvement of corticotropin-releasing factor subtype 1 receptor in the acquisition phase of learned helplessness in rats.

K Takamori1, N Kawashima, S Chaki, A Nakazato, K Kameo.   

Abstract

To determine if CRF receptor subtype 1 (CRF1) is involved in the acquisition phase of LH, we administered CRF receptor antagonists, CRA 1000 and CP-154,526, 60 min before (acquisition phase) or immediately after (consolidation phase) inescapable shocks on day 1, and 60 min before (retention phase) escape test on day 2. CRA1000 (10 mg/kg. p.o.) and CP-154,526 (30 mg/kg, p.o.) decreased the number of escape failures in the acquisition phase, but not in consolidation and retention phases. The tricyclic antidepressant, imipramine did not affect the number of escape failures in all 3 phases. Thus, the CRF1 receptor is apparently involved in the resultant escape failures in the acquisition phase of LH in rats.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11521748     DOI: 10.1016/s0024-3205(01)01217-6

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  7 in total

Review 1.  Behavioral, biological, and chemical perspectives on targeting CRF(1) receptor antagonists to treat alcoholism.

Authors:  Eric P Zorrilla; Markus Heilig; Harriet de Wit; Yavin Shaham
Journal:  Drug Alcohol Depend       Date:  2013-01-05       Impact factor: 4.492

Review 2.  Corticotropin releasing factor (CRF) receptor signaling in the central nervous system: new molecular targets.

Authors:  Richard L Hauger; Victoria Risbrough; Olaf Brauns; Frank M Dautzenberg
Journal:  CNS Neurol Disord Drug Targets       Date:  2006-08       Impact factor: 4.388

Review 3.  Development of CRF1 receptor antagonists as antidepressants and anxiolytics: progress to date.

Authors:  Glenn R Valdez
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

Review 4.  Progress in corticotropin-releasing factor-1 antagonist development.

Authors:  Eric P Zorrilla; George F Koob
Journal:  Drug Discov Today       Date:  2010-03-03       Impact factor: 7.851

Review 5.  Therapeutic utility of non-peptidic CRF1 receptor antagonists in anxiety, depression, and stress-related disorders: evidence from animal models.

Authors:  John H Kehne; Christopher K Cain
Journal:  Pharmacol Ther       Date:  2010-09-06       Impact factor: 12.310

6.  Corticotropin releasing hormone type 2 receptors in the dorsal raphe nucleus mediate the behavioral consequences of uncontrollable stress.

Authors:  Sayamwong E Hammack; Megan J Schmid; Matthew L LoPresti; Andre Der-Avakian; Mary Ann Pellymounter; Alan C Foster; Linda R Watkins; Steven F Maier
Journal:  J Neurosci       Date:  2003-02-01       Impact factor: 6.167

7.  Effects of fluoxetine on CRF and CRF1 expression in rats exposed to the learned helplessness paradigm.

Authors:  Georgina Valeria Fernández Macedo; María Laura Cladouchos; Laura Sifonios; Pablo Martín Cassanelli; Silvia Wikinski
Journal:  Psychopharmacology (Berl)       Date:  2012-09-08       Impact factor: 4.530

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.